Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer
|ClinicalTrials.gov Identifier: NCT00677326|
Recruitment Status : Terminated (Difficulty in recruiting)
First Posted : May 14, 2008
Last Update Posted : December 29, 2009
Human Genome Center, Institute of Medical Science, University of Tokyo
Information provided by:
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Terminated|
|Estimated Primary Completion Date :||April 2009|
|Actual Study Completion Date :||May 2009|
Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P, Hicklin DJ. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med. 2002 Jun 17;195(12):1575-84. Erratum in: J Exp Med 2002 Aug 19;196(4):557.
Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006 Oct 1;12(19):5841-9.